Natural Phenomenon or Process – Page 6

LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial

5 months ago talkbio0Tagged benzamide antipsychotic, first-in-class, LB-102, PANSS, Phase 2 Clinical Trials, Schizophrenia, Score

LB-102, Benzamide antipsychotic, Schizophrenia treatment, Phase II clinical trial, PANSS score reduction, First-in-class potential

Ring Therapeutics Undergoes Significant Restructuring, Laying Off Nearly Half of Its Workforce

6 months ago talkbio0Tagged Industry, restructuring, Ring (shape)

Ring Therapeutics, layoffs, workforce reduction, biotech industry, restructuring

Outlook Therapeutics Announces Strategic Workforce Reduction to Streamline Operations

6 months ago talkbio0Tagged AMD, Attitude, bevacizumab, biopharmaceutical company, cost-saving measures, Glycogen storage disease type II, Lytenava, restructuring, strategic

Outlook Therapeutics, workforce reduction, biopharmaceutical company, strategic restructuring, cost-saving measures, LYTENAVA, bevacizumab gamma, wet AMD treatment.

Editas Medicine Undergoes Major Restructuring, Laying Off 65% of Staff Including CMO Amid Failed Search for RENI-CEL Partner

6 months ago talkbio0Tagged Anemia, Sickle Cell, Chronic multifocal osteomyelitis, Editas Medicine, Gene Modification, RENI-CEL, restructuring, Thalassemia

Editas Medicine, layoffs, gene editing, biotech, RENI-CEL, sickle cell disease, thalassaemia, CMO, workforce reduction, restructuring.

Q32 Bio Inc. Faces Market Volatility After Bempikibart Program Update

6 months ago talkbio0Tagged Autoimmune Diseases, bempikibart, Bio Inc., IL-7/TSLP pathways, Market, Performance, Volatility

Q32 Bio Inc., bempikibart, autoimmune diseases, IL-7/TSLP pathways, stock performance, market volatility

Belharra Therapeutics Reduces Workforce by 40%, Laying Off 21 Employees

6 months ago talkbio0Tagged Belharra, Drug Discovery, Industry

Belharra Therapeutics, layoffs, workforce reduction, biotech industry, drug discovery

Cyclacel Pharmaceuticals Seeks Financial Lifeline Amidst Cash Crunch

6 months ago talkbio0Tagged cancer medicine, Cyclacel, development aspects, Financial cost, Financial Stress, Nasdaq, Risk, strategic alternatives

Cyclacel Pharmaceuticals, financial challenges, cost reduction, strategic alternatives, Nasdaq delisting risk, cancer medicine development

Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs

6 months ago talkbio0Tagged Agenus, Antineoplastic Agents, BOT/BAL, botensilimab/balstilimab, Financial cost, layoffs, strategic realignment

Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development

Kronos Undergoes Major Restructuring: CEO Norbert Bischofberger Exits Amid 83% Workforce Reduction

7 months ago talkbio0Tagged Bischofberger, Industry, Kronos layoffs, Norbert, restructuring

Kronos layoffs, Norbert Bischofberger, biotech industry, workforce reduction, restructuring

Biopharma Companies Continue Layoffs: Novartis, Recursion, and Kronos Reduce Staff Amid Industry Restructuring

7 months ago talkbio0Tagged Biopharma layoffs, cost-cutting measures, Drug Industry, Novartis, Recursion, restructuring

Biopharma layoffs, Novartis restructuring, Recursion, Kronos, pharmaceutical industry, workforce reduction, cost-cutting measures